Minocycline treatment for HIV-associated cognitive impairment: Results from a randomized trial

Neurology

Volumn 77, Issue 12, 2011, Pages 1135-1142

  Sacktor, N ^a   Miyahara, S ^b   Deng, L ^b   Evans, S ^b   Schifitto, G ^c   Cohen, B A ^d   Paul, R ^e   Robertson, K ^f   Jarocki, B ^g   Scarsi, K ^d   Coombs, R W ^h   Zink, M C ^a   Nath, A ^a   Smith, E ⁱ   Ellis, R J ^j   Singer, E ^k   Weihe, J ^l   McCarthy, S ^m   Hosey, L ^m   Clifford, D B ⁿ  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF MISSOURI ST LOUIS   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l HIV community representative   (United States)

^m SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

ⁿ WASHINGTON UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MINOCYCLINE; PLACEBO; VIRUS RNA;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EARLY TERMINATION OF CLINICAL TRIAL; FEMALE; GLUCOSE BLOOD LEVEL; HIV ASSOCIATED COGNITIVE IMPAIRMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; MALE; MENTAL HEALTH; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUICIDAL IDEATION; TOOTH DISCOLORATION; VIRUS LOAD; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADULT; COGNITION DISORDERS; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; TREATMENT OUTCOME;

EID: 80555157650     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31822f0412     Document Type: Article

References (40)

1. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 2010;67:699-714.
2. Gendelman HE, Zheng J, Coulter CL, et al. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis 1998;178:1000-1007. (Pubitemid 28452191)
3. Ferrando S, van Gorp W, McElhiney M, et al. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 1998;12:F65-F70. (Pubitemid 28241393)
4. Sacktor N, Lyles RH, Skolasky RL, et al. Combination antiretroviral therapy improves psychomotor speed performance in HIV+homosexual men. Neurology 1999;52: 1640-1647. (Pubitemid 29220641)
5. Epstein LG, Gendelman HE. Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann Neurol 1993;33:429-436. (Pubitemid 23143022)
6. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007;69:1404-1410. (Pubitemid 47511461)
7. Kloppenburg M, Brinkman BM, de Rooij-Dijk HH, et al. The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chemother 1996; 40:934-940. (Pubitemid 26115227)
8. Yrjanheikki J, Keinanen R, Pellikka M, et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998;95: 15769-15774. (Pubitemid 29018775)
9. Ryan LA, Zheng J, Brestser M, et al. Plasma soluble CD14 and TNF-a receptor two levels correlate with cognitive dysfunction during HIV-1 infection. J Infect Dis 2001; 184:699-706.
10. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA 1996; 93:14014-14019. (Pubitemid 26424237)
11. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001;98: 14669-14664.
12. Lee PL, Yiannoutsos CT, Ernst T, et al. A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. J Magn Reson Imaging 2003;17: 625-633. (Pubitemid 36665865)
13. Teng YD, Choi H, Onario RC, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA 2004;101:3071-3076. (Pubitemid 38327736)
14. Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005;293:2003-2011. (Pubitemid 40570894)
15. Si Q, Cosenza M, Zhao M, et al. A novel action of minocycline: inhibition of HIV-1 infection in microglia and macrophages (presentation number 395.9, 2002 Neuroscience Meeting Planner). Presented at the Society for Neuroscience, Orlando, Florida, 2002.
16. Miller EN, Selnes OA, McArthur JC, et al. Neuropsychological performance in HIV-1 infected homosexual men: The Multicenter AIDS Cohort Study (MACS). Neurology 1990;40:197-203. (Pubitemid 20099421)
17. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2- seropositive men: a randomized, double-blind, placebocontrolled crossover trial. J Infect Dis 2007;196:1500-1508. (Pubitemid 351411987)
18. Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-276.
19. Klove H. Clinical neuropsychology. In: Forster FM. The Medical Clinics of North America. New York: WB Saunders; 1963.
20. Smith A. Symbol digit modalities test manual. Los Angeles: Western Psychological Services; 1973.
21. California Computerized Assessment Package (CALCAP). Los Angeles, CA: Norland Software; 1990.
22. Comalli PE, Wapner S, Werner H. Interference effects of Stroop color-word test in childhood, adulthood, and aging. J Gen Psychol 1962;100:47-53.
23. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005;19:1367-1374. (Pubitemid 41800672)
24. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
25. Albert SM, Flater SR, Clouse R, et al. Medication management skill in HIV: I: evidence for adaptation of medication management strategies in people with cognitive impairment: II: evidence for a pervasive lay model of medication efficacy. AIDS Behav 2003;7:329-338. (Pubitemid 37203919)
26. Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007;69:1314-1321. (Pubitemid 47482445)
27. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 2004;26:307-319. (Pubitemid 39277061)
28. Heseltine PNR, Goodkin K, Atkinson JH, et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol 1998; 55:41-51. (Pubitemid 28139105)
29. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988;158:1079-1083. (Pubitemid 18266060)
30. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65-70.
31. Brogden RN, Avery GS. New antibiotics: epicillin, minocycline and spectinomycin a summary of their antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1972;3:314-330.
32. Brogden RN, Speight TM, Avery GS. Minocycline: a review of its antibacterial and pharmacokinetic properties and therapeutic use. Drugs 1975;9:251-291.
33. Brundula V, Rewcastle NB, Metz LM, et al. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002;125: 1297-1308. (Pubitemid 34587139)
34. Popovic N, Schubart A, Goetz BD, et al. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002;51:215-223. (Pubitemid 34111444)
35. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000;6:797-801. (Pubitemid 30469429)
36. Wang X, Zhu S, Drozda M, et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 2003;100:10483-10487. (Pubitemid 37071904)
37. Tikka TM, Vartiainen NE, Goldsteins G, et al. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 2002; 125:722-731. (Pubitemid 34279769)
38. Arvin KL, Han BH, Du Y, et al. Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 2002;52:54-61. (Pubitemid 34693743)
39. Zhang Y, Metz LM, Yong VW, et al. Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci 2008;35:185-191. (Pubitemid 351831055)
40. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6:1045-1053. (Pubitemid 350116691)